During the past decade, National Hospital Organization Shikoku Cancer Center conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 17 clinical trials were completed, i.e. on average, 43.6% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 11 clinical trials were completed. i.e. 57.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Hospital Organization Shikoku Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 18 trials, followed by "Haruhiko Fukuda" with 8 trials sponsored, "Daiichi Sankyo, Inc." with 6 trials sponsored, "Japan Clinical Oncology Group" with 4 trials sponsored and "Merck Sharp & Dohme LLC" with 4 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 20 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Hospital Organization Shikoku Cancer Center" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 12 trials as a collaborator, "AstraZeneca" with 5 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 3 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator and "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "National Hospital Organization Shikoku Cancer Center" are "Breast Cancer" (5 trials), "Non-Small Cell Lung Cancer" (4 trials), "Gastric Cancer" (3 trials), "Prostatic Neoplasms" (3 trials) and "Cancer" (2 trials). Many other conditions were trialed in "National Hospital Organization Shikoku Cancer Center" in a lesser frequency.

Most popular intervention types in "National Hospital Organization Shikoku Cancer Center" are "Drug" (54 trials), "Procedure" (6 trials), "Other" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (12 trials), "Carboplatin" (7 trials), "Cisplatin" (7 trials), "Gemcitabine" (7 trials) and "Paclitaxel" (7 trials). Other intervention names were less common.

The vast majority of trials in "National Hospital Organization Shikoku Cancer Center" are 48 trials for "All" genders, 7 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "National Hospital Organization Shikoku Cancer Center". undefined are not yet recruiting, 10 are recruiting, 21 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in National Hospital Organization Shikoku Cancer Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in National Hospital Organization Shikoku Cancer Center, 5 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".